Advantages

We believe our human genome sequencing technology, which is based on our proprietary DNA arrays and ligation-based read technology, is superior to existing human genome sequencing methods in terms of quality, cost and scale. Because we have optimized our technology platform and our operations for the unique requirements of high-throughput complete human genome sequencing, we are able to achieve accuracy levels of 99.999% at a total cost that is significantly less than other commercially available technologies.

Advantages of our DNA nanoball arrays and our cPAL™ technology over other DNA sequencing technologies include:

High Accuracy

Our cPAL technology has very high single-read accuracy due to the intrinsic nature (high accuracy) of the ligase enzyme.  By reading each nucleotide multiple times, we achieve a consensus error rate equal to approximately 1 error in 100,000 nucleotides.

No Accumulation of Errors

Many other DNA sequencing methods employ sequential processes that cause errors to accumulate as each successive nucleotide is read, which results in a higher error rate for each successive nucleotide.  Our cPAL technology reads each nucleotide independently and as a result there is no accumulation of errors, which enables us to read successive bases without increasing our error rate.

Low Reagent Cost

Our cPAL technology uses low concentrations of low-cost commodity reagents. Our DNB™ arrays achieve a very high density of DNA on each array, which reduces the quantity, or volume, of reagents we use compared to other DNA array approaches.  The combination of low concentration of low-cost reagents and smaller quantities results in lower reagent costs compared to other DNA sequencing methods.